Seaport Therapeutics

Update in progress

SPTX (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Seaport Therapeutics is a clinical-stage biopharma developing new medicines for depression, anxiety, and other neuropsychiatric disorders. Using its Glyph platform, it advances a therapeutic pipeline, including GlyphAllo (SPT-300), an oral prodrug of allopregnanolone, and GlyphAgo (SPT-320), an oral prodrug of agomelatine. Founded in 2024, the company is based in Boston, MA.

Company score

Sentiment: 0.48; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.53; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.16; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.19; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.34; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive